AOTMiT: What will the Transparency Council address in October?

TRANSPARENCY COUNCIL MEETING NO. 40/2023 OCTOBER 9, 2023

1. Imfinzi (durvalumabum) Indication: under the drug program "Treatment of patients with biliary tract cancer (ICD-10: C22.1, C23, C24.0, C24.1, C24.8, C24.9) Decision problem: preparation of a position paper on the evaluation of the drug

2. Rinvoq (upadacitinibum) CONDITIONAL Indication: under drug program B.32. "Treatment of patients with Crohn's disease (ICD-10: K50)". Decision-making problem: preparation of a position paper on the evaluation of the drug

3. "Health policy program for detection of hearing disorders in children attending schools and institutions from the Municipality of Krakow" Decision-making problem: preparation of an opinion on the draft health policy program of local government units

4. "Program for prevention and early detection of posture defects, overweight and obesity among children of class III of elementary schools in the city of Elk for 2023-2028" Decision-making problem: preparing an opinion on the draft health policy program of local government units

TRANSPARENCY COUNCIL MEETING NO. 41/2023 OCTOBER 16, 2023

1 Justification for changes in the content of the drug program B.33. "Treatment of patients with active form of rheumatoid arthritis and juvenile idiopathic arthritis" Decision problem: preparation of an opinion

2. Valcyte Indication: cytomegalovirus infection Decision-making problem: preparation of a position on the appropriateness of granting reimbursement approval for the medicinal product

3. "Program for prevention of type 2 diabetes and cardiovascular diseases for residents of the municipality of Cieszyn for 2025-2029" Decision-making problem: preparation of an opinion on the draft health policy program of local government units

4. "Health policy program for therapeutic rehabilitation of residents of the municipality of Cieszyn for 2025-2029" Decision-making problem: preparation of an opinion on the draft health policy program of local government units

5. "Health policy program on increasing the availability of nursing and care services in the Municipality of Krakow within the framework of daily or round-the-clock stay for dependent persons not requiring institutional care and on support for their informal caregivers" 3 Decision-making problem: preparation of an opinion on the draft health policy program of local government units

TRANSPARENCY COUNCIL MEETING NO. 42/2023 OCTOBER 23, 2023

1. "Pharmaceutical care" Decision-making problem: preparation of a position paper on the assessment of the eligibility of a health care service

2. Forxiga (dapagliflozinum) Indication: type 2 diabetes mellitus, in patients treated with at least one hypoglycemic drug, with HbA1c ≥7% and with very high cardiovascular risk defined as: 1) confirmed cardiovascular disease, or 2) damage to other organs manifested by: proteinuria or left ventricular hypertrophy or retinopathy, or 3) the presence of 3 or more major risk factors among: age ≥ 55 years for men, ≥ 60 years for women, dyslipidemia, hypertension, smoking, obesity Decision problem: preparation of a position paper on the evaluation of the drug

3. "Subsidized infertility treatment by in vitro fertilization for residents of the city of Bytom for 2023-2026". Decision-making problem: preparing an opinion on the draft health policy program of local government units

TRANSPARENCY COUNCIL MEETING NO. 43/2023 OCTOBER 30, 2023

1. therapeutic hypothermia Indication: sudden cardiac arrest Decision problem: preparing an opinion

2. calquence (acalabrutinibum) Indication: under drug program B.79. "Treatment of patients with chronic lymphocytic leukemia" Decision problem: preparation of a position paper on the evaluation of the drug

3. Calcort (deflazacort) Indication: myasthenia gravis Decision-making problem: preparing a position on the appropriateness of issuing reimbursement approval for the medicinal product.

Source: AOTMiT